Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted cancer treatment.

D M Goldenberg

    Immunology Today
    |September 1, 1989
    PubMed
    Summary
    This summary is machine-generated.

    Monoclonal antibody immunoconjugates show great progress for cancer therapy. Research continues into radioimmunoconjugates, immunotoxins, chemoimmunoconjugates, and anti-immunoglobulin therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2020
    Same author

    Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.

    European journal of nuclear medicine and molecular imaging·2020
    Same author

    Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.

    Human vaccines & immunotherapeutics·2017
    Same author

    Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.

    Bioconjugate chemistry·2014

    Area of Science:

    • Oncology
    • Immunotherapy
    • Biotechnology

    Background:

    • The fourth international conference on monoclonal antibody immunoconjugates convened to discuss advancements in cancer treatment.
    • Focus areas included radioimmunoconjugates, immunotoxins, chemoimmunoconjugates, and anti-immunoglobulin therapy.

    Discussion:

    • Significant progress was reported in radioimmunoconjugates for targeted cancer therapy.
    • Ongoing research explores the therapeutic potential of immunotoxins and chemoimmunoconjugates.
    • Anti-immunoglobulin therapy is also under investigation as a novel cancer treatment strategy.

    Key Insights:

    • Monoclonal antibody immunoconjugates represent a rapidly advancing field in oncology.
    • Diverse approaches, including radioimmunoconjugates and immunotoxins, are being developed for cancer treatment.

    Related Experiment Videos

  • The conference highlighted the collaborative efforts in advancing these targeted therapies.

    • Outlook:

    • Continued development and clinical trials are expected for these immunoconjugate therapies.
    • Further research will refine the efficacy and specificity of these cancer treatments.
    • The future holds promise for enhanced patient outcomes through innovative immunoconjugate strategies.